66 -3 (35) 2021 — O.U. Mirzaabdullahozhiva., Sh.A. Zufarova — STUDY OF ANTI-VIRAL IMMUNITY POTENTIAL IN PREGNANT WOMEN WITH CHRONIC VIRAL HEPATITIS B

STUDY OF ANTI-VIRAL IMMUNITY POTENTIAL IN PREGNANT WOMEN WITH CHRONIC VIRAL HEPATITIS B

O.U. Mirzaabdullahozhiva., Toshkent Pediatric Medical Institute

Sh.A. Zufarova Toshkent Pediatric Medical Institute

Resume

The authors set the goal in this article to describe the results obtained on the study of important immunopathogenetic markers (the main interferons – IFN-alpha and gamma, IL-28 and IL-28B gene expression) for diagnosis and prognosis of CVHB in pregnant women.

The analysis of genetic studies in a healthy population for two alleles showed that OPN rs12979860 of the IL-28V gene: CC – 38%, CT – 51%, TT – 12%; OPN rs8099917 of the IL-28V gene: TT – 56%, TG – 38%, GG – 7%.

Key words: viral hepatitis B, antiviral immunity, cellular immunity, humoral immunity, pregnancy

First page

328

Last page

333

For citation: O.U. Mirzaabdullahozhiva., Sh.A. Zufarova STUDY OF ANTI-VIRAL IMMUNITY POTENTIAL IN PREGNANT WOMEN WITH CHRONIC VIRAL HEPATITIS B //New Day in Medicine 3(35)2021 328-333 https://cutt.ly/cEKHsUh

LIST OF REFERENCES:

1. Арсентьева Н.А., Семенов А.В., Тотолян Арег А. Роль полиморфизма генов цитокинов при вирусном гепатите С // Инфекция и иммунитет. – 2012. – Т. 2. №4. – С.687-698.
2. Воронцова Г.А., Кузнецова А.В., Рогачикова А.Е. и др. Возможности использования данных о генотипах ИЛ-28Б при управлении медицинской помощью пациентам с хроническим гепатитом С // Материалы V Ежегодного Всероссийского Конгресса по инфекционным болезням. – М., 2013. – С.94.
3. Лопаткина Т.Н., Кудлинский И.С. Роль полиморфизмов гена интерлейкина 28В в оценке эффективности противовирусной терапии хронического гепатита С // Клиническая гепатология. – 2011. – Т. 2. – С.28-38.
4. Филь Г.В. Полиморфизм гена ИЛ-28В в качестве критерия эффективности противовирусной терапии при хроническом вирусном гепатите С // Врач-аспирант. – 2013. – Т. 58. №3. – С.110-114.
5. Abdo A.A., Al-Ahdal M.N., Khalid S.S., et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection // Hepatology international. – 2013. – Vol. 7. №2. -P.533-538.
6. Grebely J., Petoumenos K., Hellard M., et al. Potential role for IL28B genotype in treatment decision-making in recent hepatitis C virus infection // Hepatology. – 2010. – Vol. 52. №4. – P.1216-1224.
7. Imran M., Manzoor S., Azam., Resham S. Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population // APMIS. – 2015. – Vol. 123. №4. – P.342-349.
8. Iranmanesh Z., Mollaie H.R., Arabzadeh S.A., et al. Evaluation of the frequency of the IL-28 polymorphism (rs8099917) in patients with chronic hepatitis C using Zipnucleic acid probes, Kerman, Southeast of Iran // Asian Pacific journal of cancer prevention. – 2015. – Vol. 16. №5. – P.1919-1924.
9. Isaacs A., Lindenman J. Virus interference I. The interferon // Proc R Soc Lond B Biol Sci. – 1957. – Vol. 147. – P.258-267.
10. Jeong S.H., Jung Y.K., Yang J.W., et al. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C // Clinical and molecular hepatology. – 2012. – Vol. 18. №4. – P.360-367.
11. Jung Y.K., Kim J.H., Ahn S.M., et al. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans // Journal of clinical gastroenterology. – 2013. – Vol. 47. №7. – P.644-650.
12. Schweitzer C.J., Liang T.J. Impact of host and virus genome variability on HCV replication and response to interferon // Current opinion in virology. – 2013. – Vol. 3. №5. – P.1-7.
13. Sheppard P., Kindsvogel W., Xu W., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R // Nat. Immunol. – 2003. -Vol. 4. №1. – P.63-68.
14. Zheng H., Li M., Chi B., et al. IL28B rs12979860 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis // Clinics and research in hepatology and gastroenterology. – 2015. (Epub ahead of print) doi: 10.1016/j. clinre.2015.01.009.
15. Lampertico P., Vigano M., Cheroni C., et al. IL28B polymorphisms predict interferon-related HBsAg seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B // Hepatology. – 2013. – Vol. 57. №3. – P.890-896.
16. Lopusna K., Rezuchova I., Betakova T., et al. Interferons lambda, new cytokines with antiviral activity // Acta virologica. -2013. – Vol. 57. №2. – P.171-179.
17. Sun Y., Lu Y., Xie L., et al. Interferon gamma polymorphism and hepatitis B virus-related liver cirrhosis risk in Chinese population // Cancer cell international. – 2015. – №15 – P.35.
18. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus // Gastroenterology. – 2010. – Vol. 139. №1. -P.120-129.